This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $269,280 to Cold Spring Harbor Laboratory to conduct research on a novel targeted approach for treating K-RAS(G12C) mutation-driven cancers. The research aims to develop prodrug molecules that can selectively degrade the K-RAS(G12C) oncogenic protein while simultaneously releasing cytotoxic natural products to target multiple cancer pathways. Key objectives include determining the...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $164,628 to President and Fellows of Harvard College to conduct research on defining the roles of sequence-non-specific DNA-binding domains in mammalian SWI/SNF chromatin remodeling complexes. The research aims to elucidate how these DNA-binding domains contribute to proper assembly, integrity, catalytic activity, nucleosome remodeling, genomic targeting, and DNA accessibility generation...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $163,967 to President and Fellows of Harvard College (Harvard Medical School) to conduct research on defining the functional and spatial properties of tumor-specific, tumor-infiltrating CD8 T cells. The key objectives are to: Generate patient-derived xenograft (PDX) mouse models of melanoma to test the required diversity of T cell receptors (TCRs) from tumor-infiltrating T...
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $170,640 in funding to the Dana-Farber Cancer Institute, Inc. (DFCI) from July 1, 2025 to June 30, 2027. The grant supports research to investigate the role of histone cleavage in breast cancer, specifically focusing on how the KDM4C histone demethylase drives tumor growth by preventing proteolytic cleavage of the histone H3 N-terminal tail by cathepsin L. The research aims to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,827 to New York University School of Medicine to conduct research aimed at enhancing KRAS inhibitor therapy for cancer. The key objectives are to: 1) Evaluate four serine/threonine kinase family members as synthetic lethal targets and clarify the mechanistic basis for this synthetic lethality, and 2) Use CRISPR/Cas9 "mini-libraries" to define the synthetic...
This Project Grant award of $610,656.00 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research by The Trustees of Columbia University in the City of New York to decipher epigenetic mechanisms that dictate poor responses to KRAS inhibition in lung cancer. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical investigations in critical health...
This $703,410 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University (NYU) School of Medicine to investigate molecular mechanisms underlying the transition from lung adenocarcinoma to squamous cell carcinoma, which can contribute to resistance to KRAS inhibitor therapies. The research aims to identify chromatin regulators that drive this lineage transition, and systematically decouple the...
This $2,136,715 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) is focused on harnessing DNA methylation in peripheral blood to improve colorectal cancer prevention. The primary awardee, President and Fellows of Harvard College through its Harvard T.H. Chan School of Public Health, will lead the research effort. Key sub-awards have been made to Dana-Farber Cancer Institute and Boston University to contribute...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) will support research to determine the role of Replication Protein A (RPA) in Polymerase Theta-Mediated End-Joining (TMEJ), a mutagenic DNA double-strand break repair pathway that is critical for cancer cell survival. The $125,532 award to President and Fellows of Harvard College (Harvard Medical School) will fund investigations into how RPA interacts with the TMEJ enzyme Polymerase Theta to...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $119,059 to Harvard University to conduct research using base editing techniques to elucidate the role of the RAF kinase in KRAS-driven lung cancer. The goal is to better understand RAF kinase function and regulation, including the relative activity of different RAF homo- and hetero-dimers, in order to inform future cancer therapeutic development targeting the RAF signaling pathway. The research project will utilize unbiased base editor scanning and co-mutational approaches across Harvard's Department of Chemistry and Chemical Biology and the Dana Farber Cancer Institute. The award period runs from December 16, 2024 to June 30, 2027.